Niacin
As of the edition of 20 October 2026, Niacin is a small molecule: marketed, first approved in 1979 (CA); acts on HCAR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Wampocap
- First approved
- 31 December 1979 (CA)
- Approvals on record
- 16 in 2 regions
- Holder of the most recent approval
- AbbVie; 3 holders in all
- Withdrawn from market
- 10 April 2013 (in some regions)
- Registered trials
- 117, 16 stopped early
- Disease areas
- Nutrition and metabolism; Heart and blood vessels; Hormones; Nervous system; Inherited and neonatal; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 22 | 16 | 3 | 2 |
| Phase 1 | 21 | 11 | 4 | 4 |
| Phase 2 | 21 | 12 | 4 | 2 |
| Phase 3 | 35 | 28 | 0 | 6 |
| Phase 4 | 18 | 13 | 0 | 2 |
| All trials | 117 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Later holder and Lead sponsor of trials | 1997 to now |
| Medpointe Pharmaceuticals Medpointe Healthcare | Acquired holder | 2003 to now |
| AbbVie | Acquired holder | 2012 to now |